![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: MED18 |
Gene summary for MED18 |
![]() |
Gene information | Species | Human | Gene symbol | MED18 | Gene ID | 54797 |
Gene name | mediator complex subunit 18 | |
Gene Alias | SRB5 | |
Cytomap | 1p35.3 | |
Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | Q9BUE0 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
54797 | MED18 | HCC1_Meng | Human | Liver | HCC | 1.26e-02 | -9.97e-03 | 0.0246 |
54797 | MED18 | cirrhotic1 | Human | Liver | Cirrhotic | 1.00e-04 | 5.59e-02 | 0.0202 |
54797 | MED18 | HCC1 | Human | Liver | HCC | 8.92e-04 | 1.47e+00 | 0.5336 |
54797 | MED18 | HCC2 | Human | Liver | HCC | 2.87e-03 | 1.09e+00 | 0.5341 |
54797 | MED18 | S014 | Human | Liver | HCC | 1.27e-04 | 1.65e-01 | 0.2254 |
54797 | MED18 | S015 | Human | Liver | HCC | 6.83e-04 | 2.33e-01 | 0.2375 |
54797 | MED18 | S016 | Human | Liver | HCC | 1.43e-03 | 1.39e-01 | 0.2243 |
54797 | MED18 | S029 | Human | Liver | HCC | 4.93e-04 | 1.65e-01 | 0.2581 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Liver | ![]() | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
MED18 | SNV | Missense_Mutation | c.328N>T | p.Thr110Ser | p.T110S | Q9BUE0 | protein_coding | tolerated(0.29) | benign(0.132) | TCGA-C8-A12P-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
MED18 | SNV | Missense_Mutation | novel | c.457G>T | p.Val153Leu | p.V153L | Q9BUE0 | protein_coding | tolerated(0.3) | benign(0) | TCGA-EW-A3U0-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | CR |
MED18 | insertion | In_Frame_Ins | novel | c.491_492insTTTCATTTT | p.Ser164_Leu165insPheIleLeu | p.S164_L165insFIL | Q9BUE0 | protein_coding | TCGA-BH-A0GY-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | cyotxan | SD | ||
MED18 | SNV | Missense_Mutation | rs764845335 | c.346G>A | p.Asp116Asn | p.D116N | Q9BUE0 | protein_coding | tolerated(0.16) | benign(0.007) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
MED18 | SNV | Missense_Mutation | c.481N>A | p.Glu161Lys | p.E161K | Q9BUE0 | protein_coding | deleterious(0.01) | possibly_damaging(0.75) | TCGA-C5-A1MH-01 | Cervix | cervical & endocervical cancer | Female | >=65 | III/IV | Chemotherapy | cisplatin | PD | |
MED18 | SNV | Missense_Mutation | c.163N>A | p.Glu55Lys | p.E55K | Q9BUE0 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-LP-A4AV-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
MED18 | SNV | Missense_Mutation | rs146026180 | c.410N>A | p.Arg137His | p.R137H | Q9BUE0 | protein_coding | tolerated(0.1) | possibly_damaging(0.889) | TCGA-AA-3947-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
MED18 | SNV | Missense_Mutation | c.226N>G | p.Met76Val | p.M76V | Q9BUE0 | protein_coding | tolerated(0.11) | benign(0) | TCGA-AY-6197-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
MED18 | SNV | Missense_Mutation | rs145833779 | c.568G>A | p.Ala190Thr | p.A190T | Q9BUE0 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-AJ-A3EK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | CR |
MED18 | SNV | Missense_Mutation | c.449N>A | p.Arg150His | p.R150H | Q9BUE0 | protein_coding | deleterious(0.05) | probably_damaging(0.965) | TCGA-AX-A0J1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |